Pharmacy Daily | CMA welcomes TPP deal

COMPLEMENTARY Medicines Australia has hailed the Trans Pacific Partnership agreement between Australia, the USA and other countries, saying it will have “positive implications” for Australia’s vitamins and minerals manufacturing sector. CMA ceo Carl Gibson told Pharmacy Daily advantages of the deal include more low or no tariff markets and potentially greater market access across the region. “Australian complementary medicines are highly regarded because of the focus on quality and efficacy - Australian products are clean and green and we are experiencing an export boom to Asia,” Gibson said. He said the TPP provided simpler and clearer access requirements and operating conditions in countries including Malaysia, Mexico and Vietnam. MEANWHILE the Generic and Biosimilar Medicines Association has also welcomed the TPP provision which does not extend the data exclusivity period for medicines beyond five years. In contrast, Medicines Australia has warned that this is a “disappointing outcome and a missed opportunity to stimulate and grow the Australian biopharmaceutical industry. MA said the five year period lags behind key global competitors and collaborators such as the US, Canada, the EU and Japan

---

The above article was sent to subscribers in Pharmacy Daily's issue from 08 Oct 15
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Oct 15